Exicure Inc Stock News
$8.77
2.45%
yesterday
Nasdaq,
Jun 13, 10:00 pm CET
Exicure Inc Stock News
Neutral
Business Wire
●
17 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q.
Neutral
Business Wire
●
about one month ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant.
Neutral
Business Wire
●
2 months ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma.
Neutral
Business Wire
●
2 months ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML).
Neutral
Business Wire
●
3 months ago
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Full Year 2024 Financial Results.
Neutral
Business Wire
●
3 months ago
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Issuance of New Patent in Australia.
Neutral
Business Wire
●
5 months ago
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Neutral
Business Wire
●
5 months ago
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
